Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona’s proprietary technology to enhance BeiGene’s research capabilities. Financial details of the agreement have not been disclosed.
Access to Harbour Mice HCAb Platform
The partnership builds upon an existing collaboration initiated in 2018, which involved the Harbour Mice H2L2 platform. Under the latest agreement, BeiGene will gain access to Nona Biosciences’ Harbour Mice HCAb platform. This platform is a significant asset in the biotech industry, offering a unique approach to antibody discovery and development.
Implications for BeiGene and the Biotechnology Industry
The ability for BeiGene to utilize the Harbour Mice HCAb platform is expected to bolster the company’s antibody discovery efforts, potentially leading to the development of novel therapeutics. This collaboration highlights the growing trend of partnerships between biopharmaceutical companies to leverage cutting-edge technologies and accelerate drug discovery processes.-Fineline Info & Tech
